Abstract
Advances in tumor immunology are supporting the clinical implementation of several immunological approaches to cancer in the clinical setting. However, the alternate success of current immunotherapeutic regimens underscores the fact that the molecular mechanisms underlying immune-mediated tumor rejection are still poorly understood. Given the complexity of the immune system network and the multidimensionality of tumor/host interactions, the comprehension of tumor immunology might greatly benefit from high-throughput microarray analysis, which can portrait the molecular kinetics of immune response on a genome-wide scale, thus accelerating the discovery pace and ultimately catalyzing the development of new hypotheses in cell biology. Although in its infancy, the implementation of microarray technology in tumor immunology studies has already provided investigators with novel data and intriguing new hypotheses on the molecular cascade leading to an effective immune response against cancer. Although the general principles of microarray-based gene profiling have rapidly spread in the scientific community, the need for mastering this technique to produce meaningful data and correctly interpret the enormous output of information generated by this technology is critical and represents a tremendous challenge for investigators, as outlined in the first section of this book. In the present Chapter, we report on some of the most significant results obtained with the application of DNA microarray in this oncology field.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Pardoll DM. Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol 2002;2:227–38.
Mocellin S, Mandruzzato S, Bronte V et al. Part I: Vaccines for solid tumours. Lancet Oncol 2004;5:681–9.
Mocellin S, Semenzato G, Mandruzzato S et al. Part II: Vaccines for haematological malignant disorders. Lancet Oncol 2004;5:727–37.
Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001;411:380–4.
Pinkel D, Segraves R, Sudar D et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet 1998;20:207–11.
Broude NE. Differential display in the time of microarrays. Expert Rev Mol Diagn 2002;2:209–16.
Velculescu VE, Zhang L, Vogelstein B et al. Serial analysis of gene expression. Science 1995;270:484–7.
Brown PO, Botstein D. Exploring the new world of the genome with DNA microarrays. Nat Genet 1999;21:33–7.
Goldenfeld N, Kadanoff LP. Simple lessons from complexity. Science 1999;284:87–9.
Staudt LM, Brown PO. Genomic views of the immune system*. Annu Rev Immunol 2000;18:829–59.
Ricciardi-Castagnoli P, Granucci F. Opinion: Interpretation of the complexity of innate immune responses by functional genomics. Nat Rev Immunol 2002;2:881–9.
Keil D, Luebke RW, Pruett SB. Quantifying the relationship between multiple immunological parameters and host resistance: Probing the limits of reductionism. J Immunol 2001;167:4543–52.
Mocellin S, Provenzano M, Rossi CR et al. DNA array-based gene profiling: From surgical specimen to the molecular portrait of cancer. Ann Surg 2005;241:16–26.
Kallioniemi OP, Wagner U, Kononen J et al. Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet 2001;10:657–62.
Le Naour F. Contribution of proteomics to tumor immunology. Proteomics 2001;1:1295–1302.
Marincola FM, Jaffee EM, Hicklin DJ et al. Escape of human solid tumors from T-cell recognition: Molecular mechanisms and functional significance. Adv Immunol 2000;74:181–273.
Toulouse A, Loubeau M, Morin J et al. RARbeta involvement in enhancement of lung tumor cell immunogenicity revealed by array analysis. FASEB J 2000;14:1224–32.
Mocellin S, Rossi CR, Nitti D. Cancer vaccine development: On the way to break immune tolerance to malignant cells. Exp Cell Res 2004;299:267–78.
Garnett CT, Palena C, Chakraborty M et al. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 2004;64:7985–94.
Renkvist N, Castelli C, Robbins PF et al. A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 2001;50:3–15.
van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643–7.
Cox AL, Skipper J, Chen Y et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 1994;264:716–9.
Maecker B, von B-B, Anderson KS et al. Linking genomics to immunotherapy by reverse immunology—‘immunomics’ in the new millennium. Curr Mol Med 2001;1:609–19.
Young AN, Amin MB, Moreno CS et al. Expression profiling of renal epithelial neoplasms: A method for tumor classification and discovery of diagnostic molecular markers. Am J Pathol 2001;158:1639–51.
Takahashi M, Rhodes DR, Furge KA et al. Gene expression profiling of clear cell renal cell carcinoma: Gene identification and prognostic classification. Proc Natl Acad Sci USA 2001;98:9754–9.
Boer JM, Huber WK, Sultmann H et al. Identification and classification of differentially expressed genes in renal cell carcinoma by expression profiling on a global human 31,500-element cDNA array. Genome Res 2001;11:1861–70.
Shi YY, Wang HC, Yin YH et al. Identification and analysis of tumour-associated antigens in hepatocellular carcinoma. Br J Cancer 2005;92:929–34.
Yoshitake Y, Nakatsura T, Monji M et al. Proliferation potential-related protein, an ideal esophageal cancer antigen for immunotherapy, identified using complementary DNA microarray analysis. Clin Cancer Res 2004;10:6437–48.
Mathiassen S, Lauemoller SL, Ruhwald M et al. Tumor-associated antigens identified by mRNA expression profiling induce protective anti-tumor immunity. Eur J Immunol 2001;31:1239–46.
Wang T, Fan L, Watanabe Y et al. L552S, an alternatively spliced isoform of XAGE-1, is over-expressed in lung adenocarcinoma. Oncogene 2001;20:7699–709.
Weinschenk T, Gouttefangeas C, Schirle M et al. Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res 2002;62:5818–27.
Banchereau J, Briere F, Caux C et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000;18:767–811.
Lanzavecchia A, Sallusto F. Regulation of T cell immunity by dendritic cells. Cell 2001;106:263–266.
Chen Z, Gordon JR, Zhang X et al. Analysis of the gene expression profiles of immature versus mature bone marrow-derived dendritic cells using DNA arrays. Biochem Biophys Res Commun 2002;290:66–72.
Suciu-Foca Cortesini N, Piazza F, Ho E et al. Distinct mRNA microarray profiles of tolerogenic dendritic cells. Hum Immunol 2001;62:1065–72.
Chen Z, Dehm S, Bonham K et al. DNA array and biological characterization of the impact of the maturation status of mouse dendritic cells on their phenotype and antitumor vaccination efficacy. Cell Immunol 2001;214:60–71.
Figdor CG, De Vries IJ, Lesterhuis WJ et al. Dendritic cell immunotherapy: Mapping the way. Nat Med 2004;10:475–80.
Ju XS, Hacker C, Madruga J et al. Towards determining the differentiation program of antigen-presenting dendritic cells by transcriptional profiling. Eur J Cell Biol 2003;82:75–86.
Huang H, Li F, Gordon JR et al. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression. Cancer Res 2002;62:2043–51.
Zhang X, Chen Z, Huang H et al. DNA microarray analysis of the gene expression profiles of naive versus activated tumor-specific T cells. Life Sci 2002;71:3005–17.
Carrabba MG, Castelli C, Maeurer MJ et al. Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: Role of Melan-A/MART-1 optimized analogues. Cancer Res 2003;63:1560–7.
Verdeil G, Puthier D, Nguyen C et al. Gene profiling approach to establish the molecular bases for partial versus full activation of naive CD8 T lymphocytes. Ann NY Acad Sci 2002;975:68–76.
Keilholz U, Weber J, Finke JH et al. Immunologic monitoring of cancer vaccine therapy: Results of a workshop sponsored by the Society for Biological Therapy. J Immunother 2002;25:97–138.
Wang E, Marincola FM. A natural history of melanoma: Serial gene expression analysis. Immunol Today 2000;21:619–23.
Wang E, Miller LD, Ohnmacht GA et al. Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res 2002;62:3581–6.
Mocellin S, Panelli MC, Wang E et al. The dual role of IL-10. Trends Immunol 2003;24:36–43.
Mocellin S, Panelli M, Wang E et al. IL-10 stimulatory effects on human NK cells explored by gene profile analysis. Genes Immun 2004;5:621–30.
Kelly JM, Darcy PK, Markby JL et al. Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat Immunol 2002;3:83–90.
Mocellin S, Rossi C, Nitti D et al. Dissecting tumor responsiveness to immunotherapy: The experience of peptide-based melanoma vaccines. Biochim Biophys Acta Rev Cancer 2003;1653:61–71.
Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4:321–7.
Panelli MC, Wang E, Phan G et al. Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration. Genome Biol 2002;3:RESEARCH0035.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Landes Bioscience and Springer Science+Business Media
About this chapter
Cite this chapter
Mocellin, S., Lise, M., Nitti, D. (2007). Tumor Immunology. In: Mocellin, S. (eds) Microarray Technology and Cancer Gene Profiling. Advances in Experimental Medicine and Biology, vol 593. Springer, New York, NY. https://doi.org/10.1007/978-0-387-39978-2_14
Download citation
DOI: https://doi.org/10.1007/978-0-387-39978-2_14
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-39977-5
Online ISBN: 978-0-387-39978-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)